Clinical trials: Monocytes
Sepsis, Septic Shock
Early and Late Neutrophil CD64 and Monocyte HLA-DR as Biomarkers for Septic Shock
Study Summary: Neutrophil CD64 \& Monocyte HLA-DR in Septic Shock What is studied? Doctors looked at two blood markers: Neutrophil CD64 (nCD64): rises quickly when the body fights infection.
- Trial name
- NCT07401329
- Where
- India
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Pandit Bhagwat Dayal Sharma, PGIMS, Rohtak
Physical Activity, Central Obesity
Is Physical Activity, Obesity, and Ethnicity Associated With the Tethering and Migration of Pro-inflammatory Monocytes?
Being south Asian or centrally obese may be associated with an increased risk of inflammation. The investigators are seeking to investigate whether this is the case by recruiting white European and south Asian men who are lean or…
- Conditions
- Physical Activity, Central Obesity, Inflammation
- Trial name
- NCT04761081
- Testing
- Habitual physical activity assessment
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Loughborough University
Sepsis, SIRS(Systemic Inflammatory Response Syndrome)
Detection Of Monocytes/Macrophages Function And Tim-3 Expression In Septic Patients
The imbalance between anti- and pro-inflammation often occurs in patients with sepsis. And continuous such imbalance could lead to immunoparalysis, which is characterized by loss of delayed type hypersensitivity, failure of…
- Trial name
- NCT01801839
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Leukemia
Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia
RATIONALE: A screening test, such as My Profile Pediatric Assay, may help doctors predict a patient's risk of relapse and plan better treatment for acute myeloid leukemia.
- Trial name
- NCT01438138
- Testing
- diagnostic laboratory biomarker analysis
- Volunteers
- 98 people
- Sponsor
- Children's Oncology Group
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
This phase I trial is studying the side effects and best dose of sorafenib in treating patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, or chronic myelogenous leukemia.
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT00131989
- Testing
- sorafenib tosylate, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Sudden Deafness, Sensorineural Hearing Loss
Autologous Blood Monocyte Vesicles for the Treatment of Sudden Deafness
Sudden deafness is a common emergency in otorhinolaryngology. As the etiology and mechanism of sudden deafness remains unknown, there is no specific treatment.
- Trial name
- NCT06707389
- Testing
- autologous blood monocyte vesicles (lower dose), Methylprednisolone, autologous blood monocyte vesicles (higher dose)
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Thyroid Cancer
Myeloid Cell Reprogramming in Thyroid Carcinoma
This study investigates the reprogramming of myeloid cells in patients with thyroid carcinoma. The investigators hypothesize that tumor-derived factors change the function of myeloid cells (peripheral blood and bone…
- Trial name
- NCT03397238
- Where
- Netherlands
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Leukemia
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00528398
- Testing
- cytarabine, idarubicin
- Where
- 2 sites in United States
- Volunteers
- 111 people
- Sponsor
- City of Hope Medical Center
Rheumatoid Arthritis
IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
The purpose of the study is to better understand the factors present in the cells of inflamed joints of patients with arthritis that may cause rheumatoid arthritis.
- Trial name
- NCT02451748
- Testing
- Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Illinois Chicago
Osteosarcoma
Monocyte Phenotypic and Functional Differences
The purpose of this study is to identify phenotypic (cell surface receptor expression) and functional differences in monocyte populations in humans with osteosarcoma as compared to published historical data on normal human…
- Trial name
- NCT02132182
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Duke University
Leukemia
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00070174
- Testing
- asparaginase, busulfan, cyclophosphamide
- Where
- 148 sites in United States, Australia and 3 more
- Volunteers
- 350 people
- Sponsor
- Children's Oncology Group
Immunological Status, Healthy Volunteers
Critical Food Ingredients on Immunocompetence to Prevent the Risk and Development of Obesity/Metabolic Syndrome
Double-blind cross-over intervention where the volunteers were randomized into two groups who, after receiving nutritional counseling, received two formulations in the form of a cookie: Group 1, commercial formulation and Group…
- Conditions
- Immunological Status, Healthy Volunteers, Healthy Volunteers - Male and Female
- Trial name
- CricoImNut (NCT07496320)
- Testing
- Administration of a commercial cookie formulation, Immunonutritional_2
- Where
- Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- IMDEA Food
Leukemia
Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00268242
- Testing
- Gemcitabine Hydrochloride, Mitoxantrone Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- The Cleveland Clinic
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7)
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
This phase II trial studies the side effects and how well omacetaxine mepesuccinate, cytarabine, and decitabine work in treating older patients with newly diagnosed acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT02029417
- Testing
- cytarabine, omacetaxine mepesuccinate, decitabine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Roswell Park Cancer Institute
Migraine, Headache
miR-155 Expression in Episodic and Chronic Migraine
Migraine is a common, yet often disabling, neurological disease that affects over 1 billion people around the world. It's the second most disabling disease globally and the leading cause of disability for people under the age of…
- Conditions
- Migraine, Headache, Pain, Chronic Migraine
- Trial name
- NCT05891808
- Where
- Italy
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- IRCCS National Neurological Institute "C. Mondino" Foundation
Leukemia, Myelodysplastic Syndromes
Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
RATIONALE: Gathering information about patients with myelodysplastic syndrome or acute myeloid leukemia who are discharged after finishing chemotherapy, or who stay in the hospital until blood counts return to normal, may help…
- Trial name
- NCT00844441
- Testing
- medical chart review, questionnaire administration, quality-of-life assessment
- Where
- 3 sites in United States, Switzerland
- Volunteers
- 96 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia
Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- AML1107 (NCT00775593)
- Testing
- clofarabine, temsirolimus
- Where
- 19 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Osteoarthritis
Microfluidic Organotypic Model for Monocyte Transendothelial Migration to the Joint in Obese Osteoarthritic Patients
Osteoarthritis (OA) is the fastest growing cause of disability worldwide due to population ageing and increasing obesity incidence.
- Trial name
- MOTEM (NCT03347500)
- Testing
- use of patient-derived biological samples
- Volunteers
- 88 people
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Leukemia
Total-Body Irradiation Plus Stem Cell Transplantation And White Blood Cell Infusion in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by radiation therapy used to kill tumor cells.
- Trial name
- NCT00005801
- Testing
- therapeutic allogeneic lymphocytes, peripheral blood stem cell transplantation, radiation therapy
- Where
- 2 sites in United States
- Sponsor
- University of Colorado, Denver